Last reviewed · How we verify

NCT03851809

Safety and Efficacy of Wendan Decoction in Acute Moderated to Severe Brain Injury

Completed Phase 2, PHASE3 Last updated 22 February 2019
What this trial tests

Phase 2, PHASE3 trial testing Wendan decoction combination in acute brain injury in Acute Brain Injury in 60 participants. Completed in 31 January 2016.

Timeline
1 June 2014
Primary endpoint
31 July 2015
31 January 2016

Quick facts

Lead sponsorTaichung Tzu Chi Hospital
PhasePhase 2, PHASE3
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment60
Start date1 June 2014
Primary completion31 July 2015
Estimated completion31 January 2016

Drugs / interventions tested

Conditions studied

Sponsor

Taichung Tzu Chi Hospital

Who can join

Adults 18 to 80, any sex, with Acute Brain Injury. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Efficacy and safety of Traditional Chinese Medicine (Wendan decoction) combined with conventional neurologic intensive care in patients with acute moderated to severe brain injury in early stage - A randomized controlled study.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Acute Brain Injury

Currently open trials in the same condition.

Other Taichung Tzu Chi Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03851809.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing